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Abstract
Introduction We performed a retrospective analysis of HER2-
overexpressing metastatic breast cancer patients to describe
clinical outcomes of those who, despite progression of the
disease (PD), maintained trastuzumab for multiple
chemotherapy lines. We also compared survival of these
patients with that of those who halted trastuzumab at first PD.
Methods We identified 101 patients treated between July 2000
and January 2007. Nineteen were still receiving the first-line
trastuzumab-based treatment without evidence of PD and were
not included in this analysis. Of the remaining 82 patients, 59
retained trastuzumab for one or more additional lines of
chemotherapy after PD, according to our institution policy.
Twenty-three patients who changed treating institution and
stopped trastuzumab at first progression were used as a control
group.
Results For patients retaining trastuzumab, the median follow-
up was 39.6 months. Clinical outcomes showed the typical
degradation between first and second lines of therapy which we
would expect by halting trastuzumab at first progression.
Response rates were 35% and 16% and median times to
progression were 7.25 and 5.25 months for the first and second
lines of trastuzumab therapy, respectively. The median overall
survival (OS) rates were 70 months for patients who retained
trastuzumab and 56 months for patients who halted the drug
(hazard ratio [HR] 0.87, 95% confidence interval [CI] 0.51 to
1.18; P = 0.52). If we consider OS from the start of trastuzumab
therapy, the figures are 53.9 and 34.8 months, respectively (HR
0.78, 95% CI 0.58 to 1.32; P = 0.2).
Conclusion A nonstatistically significant trend of improved
survival for patients retaining trastuzumab is observed. This is in
line with most retrospective analyses and recent randomized
data. Retaining trastuzumab after progression is a reasonable
option, but further randomized data are warranted to better
define its role in comparison with other available options.
Introduction
Trastuzumab is a humanized anti-HER2 monoclonal antibody
directed against the HER2 protein (p185HER2/neu), which is
the product of the HER2 proto-oncogene (also designated as
c-erbB-2 or HER2/neu). HER2 is overexpressed in approxi-
mately 20% to 25% of breast tumors [1,2]. This alteration is
associated with poor prognosis and may affect the response
to hormonal therapy and chemotherapy [3,4]. Trastuzumab
demonstrated a benefit as a single agent in first- or second-
line treatment of HER2-overexpressing (HER2+) metastatic
breast cancer (MBC) [5,6]. Furthermore, in two randomized
trials involving chemotherapy-naive HER2+  MBC patients,
trastuzumab in combination with chemotherapy yielded a
longer time to disease progression and a longer median sur-
vival as compared with chemotherapy alone [7,8]. According
to these results, trastuzumab has been approved for use in
combination with taxanes as first-line treatment of HER2+
MBC and its administration is usually allowed after completion
of chemotherapy up to the progression of the disease (PD),
the time when trastuzumab should be withdrawn and a
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second-line chemotherapy started (see regulatory approval by
the Food and Drug Administration in the US or by the Euro-
pean Medicines Agency in Europe).
The choice to stop trastuzumab at disease progression indi-
rectly derives from the traditional use of cytotoxic treatments,
whose discontinuation upon disease progression is warranted
because both there is no experimental evidence of a benefit in
continuing the same treatment and overlapping toxicity does
not permit concomitant delivery of non-crossresistant cyto-
toxic agents. It has been argued, however, that this paradigm
may not apply to molecularly targeted drugs like trastuzumab.
For instance, preclinical data suggest that continuation of
treatment with trastuzumab is required for sustained tumor
control in breast cancer in nude mice [9], thus supporting
treatment extension after first-line progression. Moreover,
although the exact mechanism of action of this drug is unclear,
preclinical models indicate a synergistic antitumoral effect
between trastuzumab and chemotherapy [10]. Therefore,
some authors have hypothesized that trastuzumab administra-
tion should continue despite disease progression in order to
take advantage of a potential synergistic interaction with sec-
ond-line chemotherapy. More recent preclinical experimental
data are contradictory in this regard. Tripathy and colleagues
[11] suggest that breast cancer cell proliferation is inhibited
partially by continuing trastuzumab treatment even after the
development of resistance to the drug. Similarly, Shirane and
colleagues [12] show that retaining trastuzumab therapy
improves the cytotoxic effect of taxanes against trastuzumab-
resistant xenografts in nude mice. Conversely, Nahta and col-
leagues [13] report that the continued exposure to trastuzu-
mab after development of resistance did not improve the
efficacy of the chemotherapeutic drug vinorelbine.
From a clinical standpoint, relevant data are scanty and contra-
dictory [14-21] and therefore whether to continue the admin-
istration of trastuzumab beyond disease progression remains
an unanswered question. To help resolve this issue, we
present a retrospective analysis of the series of patients
treated with trastuzumab at our institution, in order to describe
characteristics and clinical outcomes of patients who halted
the treatment at first evidence of progression as compared
with those who were maintained on trastuzumab in spite of the
PD.
Materials and methods
We searched clinical and pharmacy records of the Oncology
Division at the University of Naples 'Federico II', Italy, to identify
patients with HER2+ MBC who had received at least one line
of trastuzumab therapy between July 2000 and January 2007.
The policy adopted at our institution in that period was to con-
tinue trastuzumab after progression for multiple lines of chem-
otherapy, if medically feasible. After first progression, however,
some patients decided to receive further therapies at other
institutions and usually were put off trastuzumab. Because
their decision was apparently based on nonmedical reasons,
we followed them up by telephone calls and used their survival
data as a control in this analysis. All patients who retained tras-
tuzumab therapy after progression gave their written informed
consent to the off-label use of the drug. Trastuzumab was
administered according to either the standard weekly regimen
(loading dose of 4 mg/kg and then 2 mg/kg weekly) or the 3-
weekly regimen (loading dose of 8 mg/kg and then 6 mg/kg
every 3 weeks). HER2 expression was assessed by immuno-
histochemistry with the polyclonal Dako test (Dako, Glostrup,
Denmark) and scored for the majority of patients as 3+ or 2+.
For tumors scoring 2+, a fluorescence in situ hybridization test
was mandatory to confirm HER2 gene amplification. Some
patients were tested by a monoclonal antibody (CB11) and
were declared HER2+ if they exhibited intense and diffuse
membrane staining in more than 10% of tumor cells. Tumor
response was evaluated by imaging procedures such as com-
puted tomography scan or magnetic resonance imaging or by
clinical examination. Tumor response was based on RECIST
(Response Evaluation Criteria in Solid Tumors) criteria, when
applicable. In the absence of measurable lesions, the disease
was considered stable unless a clinical progression was iden-
tified based on the judgment of the treating physician.
Statistical analysis
Objective response rate (ORR) was defined as the sum of
complete response and partial response (CR + PR). Clinical
benefit was defined as the sum of ORR and stable disease
lasting at least 24 weeks (CR + PR + SD). Time to progres-
sion (TTP) was defined as the time from the start of each treat-
ment with trastuzumab to the date of documented
progression. Overall survival (OS) was defined as the time
from the date of diagnosis of metastatic disease until death
from any cause. Since some patients were not treated with
trastuzumab as the first line of therapy for metastatic disease,
we also calculated trastuzumab-start OS (tsOS), defined as
the time from the initiation of trastuzumab treatment until
death. To reduce further the bias derived from the effect of
trastuzumab first-line therapy, we also calculated post-pro-
gression OS (ppOS), defined as the time from the first docu-
mented progression after the trastuzumab therapy until death
from any cause. For OS, tsOS, and ppOS, surviving patients
were censored at the time of their last follow-up. OS, tsOS,
and ppOS were estimated by the Kaplan-Meier method. All P
values were two-sided and were considered significant if their
value was less than 0.05.
Results
One hundred one patients with trastuzumab-treated MBC
were identified. Of these, 19 were still receiving the first line of
trastuzumab-based therapy without progression and therefore
are not included in the present analysis. Among the remaining
82 patients, 23 had stopped trastuzumab to the first progres-
sion because they elected to continue therapy elsewhere,Available online http://breast-cancer-research.com/content/10/4/R60
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whereas 59 had retained it for one or more additional lines of
chemotherapy.
Patient characteristics
Characteristics of patients according to whether trastuzumab
was halted or retained upon progression are summarized in
Table 1. Trastuzumab-based treatment was used as first-line
therapy for 35 (59%) patients retaining trastuzumab and for
12 (52%) patients halting trastuzumab at progression. Most
patients received trastuzumab in combination with a single
chemotherapeutic agent. The most frequently administered
cytotoxic drugs were taxanes (docetaxel or paclitaxel) and
then vinorelbine in both groups of patients and for either first
or subsequent treatment lines. Among the 59 patients retain-
ing trastuzumab, 27 kept on trastuzumab up to a third line of
chemotherapy and 14 up to a fourth line. Overall, there is no
statistically significant difference in the distribution of main
patient characteristics between the two groups. However, a
nonstatistically significant imbalance was observed for age of
less than 50 years, poorly differentiated (G3) tumors, adjuvant
administration of anthracycline ± taxanes, and involvement of
at least two metastatic sites, which were all more frequent
among patients retaining trastuzumab.
Clinical outcomes
Clinical outcomes of patients retaining trastuzumab beyond
disease progression are summarized in Table 2. The median
follow-up was 39.6 months (95% confidence interval [CI] 29.5
to 56.5 months), and the median duration of trastuzumab ther-
apy was 16.5 months. As can be seen, after the first line of
treatment, ORR, clinical benefit, and TTP show the typical
deterioration that is traditionally observed with chemotherapy
alone. Most patients halting trastuzumab at first PD were not
evaluable for tumor response assessment because they usu-
ally continued treatment at other institutions. However, we
were able to follow them up for survival data by telephone
calls. We have recorded 20 and 8 deaths in the groups retain-
ing and halting trastuzumab, respectively. Figure 1 depicts the
OS curve for both groups, showing a nonstatistically signifi-
cant trend of improved survival for patients continuing the drug
after progression (hazard ratio [HR] 0.87, 95% CI 0.58 to
1.32). A similar nonsignificant trend favoring patients who
retained trastuzumab was observed for tsOS (Figure 2) with
an HR of 0.78 (95% CI 0.51 to 1.18). Where ppOS was con-
cerned, there is also a trend in favor of the group continuing
trastuzumab beyond PD, though nonstatistically significant
(HR 0.85, 95% CI 0.56 to 1.29) (Figure 3). Safety was not a
primary objective of this retrospective analysis; however, it is
worth noting that only one symptomatic cardiac event was
recorded after first-line therapy for patients keeping on
trastuzumab.
Discussion
Trastuzumab has dramatically changed the treatment of
HER2+ MBC. Its combination with chemotherapy is the main-
stay of first-line treatment of breast tumors with HER2 amplifi-
cation/overexpression. According to the regulatory approval in
the US and Europe, trastuzumab should be administered up to
the first evidence of PD. Many clinicians, however, prolong the
administration of the drug for various chemotherapy lines in the
attempt to exploit a potential synergism with further chemo-
therapy regimens. However, this 'off-label' practice, which has
never been proven to be effective, has important drawbacks,
such as a dramatic increase of treatment-related costs and a
potential yield of treatment-related adverse events.
From a safety perspective, however, available data seem reas-
suring. In our study, patients were routinely monitored for car-
diac events by clinical examination and every cycle evaluation
of left ventricular ejection fraction. We recorded only one
symptomatic cardiac event during prolonged administration of
trastuzumab after first PD, which is in line with the results of
the H0659g trial, a large extension trial specifically designed
to evaluate the safety profile of trastuzumab beyond disease
progression. In the H0659g trial, indeed, no new specific
adverse events were seen with any particular chemotherapy
regimen or with prolonged administration of trastuzumab up to
40 months. No cumulative toxicities emerged and cardiac dys-
function was uncommon, suggesting that the long-term trastu-
zumab treatment is well tolerated and that the development of
trastuzumab-associated cardiac dysfunction is not determined
by the duration of trastuzumab treatment or by the cumulative
dose of the drug [22].
From an efficacy perspective, we were unable to lend clear
support to this 'off-label' use of trastuzumab. This is based par-
ticularly on the observation that patients retaining trastuzumab
for multiple chemotherapy lines experienced, in our series, a
progressive worsening of treatment-related outcomes. This
appears similar to what we would expect with chemotherapy
alone, thus casting doubts on the potential advantage of keep-
ing the patients on trastuzumab after the first progression. Var-
ious authors have carried out similar analyses showing
heterogeneous results. As far as response rate is concerned,
many authors reported results that are analogous to ours
[14,17,19,20], but in two studies [18,21] response rates have
appeared very similar for first- and second-line trastuzumab-
based treatments (Table 3), thus supporting the hypothesis of
a potentiation of further chemotherapy regimens by retaining
trastuzumab after progression. When TTP is analyzed, studies
have again shown inconsistent results (Table 3). In our study,
the median TTP was 2.0 months shorter for second-line treat-
ment as compared with first-line. A similar TTP degradation is
reported by Montemurro and colleagues [20] (median TTP:
9.0 versus 6.3 months, first versus second line, respectively)
and by Metro and colleagues [19] (median TTP: 9.5 versus 6.7
months, first versus second line, respectively). Conversely, in
the Spanish and Austrian studies [14,17], TTP is approxi-
mately constant between the first and second lines, whereas
in the global retrospective analysis by Gelmon and colleaguesBreast Cancer Research    Vol 10 No 4    Cancello et al.
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[18], the TTP of the second trastuzumab regimen is even
longer than the first one (26 versus 23.5 weeks, respectively).
At analytical examination, we were unable to identify distin-
guishing characteristics of these studies which may explain
such different results. However, it has to be underscored that
this kind of study is prone to many biases. For instance, the
Table 1
Patient characteristics
Patients retaining trastuzumab Patients halting trastuzumab
Percentage Number 59 Percentage Number 23
Age in years, mean (range)a 51 (26–74) 58 (36–77)
<50 years 41 24 22 5
≥ 50 years 59 35 78 18
Oestrogen receptor/Progesterone receptor
+/+ 49 29 43 10
+/- 10 6 9 2
-/- 39 23 39 9
Unknown 2 1 9 2
Node
Negative 12 7 13 3
Positive 66 39 52 12
Unknown 22 13 35 8
Grade
1–2 10 6 26 6
35 4 3 2 4 3 1 0
Unknown 36 21 31 7
Adjuvant Therapy
Anthracycline 44 26 31 7
Anthracycline/taxane 10 6 13 3
No anthracycline/taxane 46 27 56 13
HER2
2+b 12 7 9 2
3+ 56 33 48 11
Other (positive)c 32 19 43 10
Site of disease before trastuzumab therapyd
1 site 59 35 78 18







aAge at the time when trastuzumab therapy was started. bAll 2+ patients had amplification of HER2 gene (fluorescence in situ hybridization-
positive). cPositive was indicated by a pathologist as intense and diffuse membrane staining in more than 10% of tumor cells. dSite information 
refers to the start of trastuzumab treatment.Available online http://breast-cancer-research.com/content/10/4/R60
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reported outcomes for the trastuzumab-based regimens may
have been heavily influenced by several factors, like the kind of
chemotherapy used and the characteristics of patients (that is,
prior chemotherapy exposure, disease-free interval, tumor bur-
den, dominant metastatic site, and so on). Therefore, any com-
bination of results for first- and second-line treatments may
have been observed just for the play of such factors or by
chance, making it unreasonable to draw conclusions or
hypotheses based on these data.
A more informative approach is to compare the survival of
patients who maintained trastuzumab with that of patients who
stopped the drug upon first progression, provided that no
major patient characteristic has driven the treatment choice.
Only four studies, including ours, reported such data, with
three of them showing a longer survival for patients who main-
tained trastuzumab. In the Italian study by Montemurro and col-
leagues [20], survival of patients who continued or
discontinued trastuzumab is practically identical. In the Ger-
Table 2
Clinical outcomes of trastuzumab beyond disease progression
Median follow-up 39.6 months
Median duration of trastuzumab therapy 16.5 months




Third-line trastuzumab (n = 
26)
Fourth-line trastuzuamb (n 
= 12)
Objective response rate
CR + PR, (number) 
percentage
(20)a 35 (9)b 16 (4)c 15 (0) 0
CR, (number) 
percentage
(6) 10.5 (2) 3.5 (0) 0 (0) 0
PR, (number) 
percentage
(14) 24.5 (7) 12.5 (4) 15 (0) 0
Clinical benefit, 
percentage (CR + PR + 
SD)
74 (6 + 14 + 22) 53 (2 + 7 + 20) 60 (0 + 4 + 11) 17 (0 + 0 + 2)
Time to progression in 
months, median (range)
7.25 (1.5–46.5) 5.25 (1.25–34.2) 5.25 (1–33.5) 3.75 (1–7)
aTwo patients were not evaluable. bFour patients were not evaluable. cOne patient was not evaluable. CR, complete response; PR, partial 
response; SD, stable disease.
Figure 1
Overall survival of patients retaining trastuzumab (H) and patients halt- ing trastuzumab (No H) Overall survival of patients retaining trastuzumab (H) and patients halt-
ing trastuzumab (No H).
Figure 2
Overall survival from the start of trastuzumab of patients retaining (H)  and patients halting (No H) trastuzumab Overall survival from the start of trastuzumab of patients retaining (H) 
and patients halting (No H) trastuzumab.Breast Cancer Research    Vol 10 No 4    Cancello et al.
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man study [21], a statistically significant longer survival for
patients who received two or more trastuzumab-based regi-
mens is reported. In a French study presented recently at the
San Antonio Breast Cancer Symposium, survival of patients
maintaining trastuzumab is much longer than for patients halt-
ing the drug [15]. However, this difference is so large that a
selection bias may have occurred. For instance, if patients
halting trastuzumab include those who are unfit to receive fur-
ther chemotherapy, the observed difference may well be
explained by the bad prognosis of these patients; unfortu-
nately, this issue is not clarified by the authors. Moreover, in
the French study, patients who retained trastuzumab would
seem to have a longer median disease-free interval, less vis-
ceral tumor burden, and (above all) fewer poorly differentiated
tumors; so these features could have contributed to the sur-
vival advantage for patients continuing trastuzumab.
In our study, we have found a trend toward a better survival for
patients continuing trastuzumab beyond progression; this
trend increases when we calculate OS from the start of trastu-
zumab therapy. Although statistical significance is not reached
in our analysis, we believe that these results support a possi-
ble advantage in continuing trastuzumab beyond disease pro-
gression. Indeed, our study is relatively small and the lack of a
formal statistical significance may well be ascribed to the low
statistical power of the study. Furthermore, in our series,
patients halting trastuzumab after PD were those who elected
to continue treatment at other institutions for nonmedical rea-
sons. Therefore, a major selection bias favoring survival for
these patients should not have occurred. Quite the opposite,
in our study, patients who continued trastuzumab were
younger, had tumors that were less differentiated, had
received more adjuvant chemotherapy, and (finally) had a
higher tumor burden (Table 1). Although these differences are
not statistically significant, they theoretically could have diluted
a beneficial effect of retaining trastuzumab.
Lapatinib is a tyrosine-kinase inhibitor that has been shown to
improve the efficacy of capecitabine for HER2+ patients pro-
gressing on trastuzumab-based therapy and recently has been
granted approval for the treatment of such patients. For two
reasons, however, the availability of this drug does not limit the
interest in the off-label use of trastuzumab after progression.
First, the study by Geyer and colleagues [23] did not show any
survival advantage for patients receiving lapatinib. Although
survival was not the primary endpoint, the lack of a survival
improvement remains unexplained because in that study a
crossover to lapatinib after progression was not allowed to
patients who had received capecitabine alone. A possible
explanation is that the advantage of getting lapatinib is tempo-
rary and is completely offset by a shorter ppOS for patients
randomly assigned to lapatinib. Second, if the 'principle' that
continuing trastuzumab after progression is proven effective,
reinstating trastuzumab therapy even after progression on lap-
atinib could be a valid option [23].
Three ongoing randomized trials are directly evaluating the effi-
cacy of continuing trastuzumab after progression. A European
multicenter randomized phase III study coordinated by the
German Breast Cancer Group, namely the Trastuzumab
Beyond Progression (TBP) trial, is comparing capecitabine
alone versus the combination capecitabine-trastuzumab upon
progression of a previous treatment with trastuzumab [24].
The trial started recruitment on June 2003 aiming at a target of
482 patients, but because of a low accrual the trial was closed
at 156 patients. A more pragmatic approach is followed in the
other two trials: the 'Pandora' study, which is an international
European study sponsored by F. Hoffmann-La Roche Ltd.
(Basel, Switzerland) [25], and the recently started THOR
(Trastuzumab Halted Or Retained) trial, which is an Italian
study coordinated at our institution and sponsored by F. Hoff-
mann-La Roche Ltd. [26]. The main difference of these prag-
matic studies compared with the German trial is that second-
line chemotherapy is not fixed but investigators can choose
among numerous regimens enlisted in the protocol. Quite
recently, results from the TBP trial have been presented [27],
showing that keeping trastuzumab in combination with
capecitabine after progression yields a statistically significant
improvement of TTP (8.2 versus 5.6 months; P = 0.03), but
not of OS (25.5 versus 20.4 months; P = 0.26). It remains to
be defined whether other chemotherapy regimens benefit from
trastuzumab continuation. Also, to check whether survival is
improved by continuing trastuzumab will require a longer fol-
low-up, additional data, or both.
Figure 3
Overall survival from the first documented progression after the trastu- zumab therapy of patients retaining (H) and patients halting (No H)  trastuzumab Overall survival from the first documented progression after the trastu-
zumab therapy of patients retaining (H) and patients halting (No H) 
trastuzumab.Available online http://breast-cancer-research.com/content/10/4/R60
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Conclusion
In our analysis, we observed a nonstatistically significant trend
of improved survival for patients retaining trastuzumab with
multiple lines of treatment. These results are in agreement with
most, but not all, retrospective data and provide additional
support to preliminary randomized data showing an improve-
ment of TTP. Additional randomized data are needed to better
define the role of continuing trastuzumab after progression,
with particular regard to the eventual OS improvement. Mean-
while, the 'off-label' practice of continuing trastuzumab after
progression stands as a reasonable therapeutic option, partic-
ularly for patients who are intolerant to lapatinib.
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